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ABSTRACT
Natural killer/T-cell lymphoma (NKTCL) is an aggressive non-Hodgkin lymphoma 
that has been facing limited success with conventional treatments, urging for the 
discovery of alternative strategies. Recent studies including ours have revealed that 
EZH2 and JAK-STAT signalling pathways are key contributors to NKTCL pathogenesis. 
In particular, we found that EZH2 is overexpressed and directly transcriptionally 
activates the CCND1 gene to confer growth advantage. CCND1 codes for cyclin D1, 
which complexes with CDK4/6 to promote G1 to S phase transition. Therefore in this 
study we investigated whether inhibiting both JAK1/2 and CDK4/6, using LEE011 
and ruxolitinib respectively is effective in NKTL. We first demonstrate that separate 
LEE011 and ruxolitinib treatment is sufficient to cause growth inhibition of NKTCL 
cells. More importantly, we found that there is synergistic growth inhibitory effects 
on NKTCL cells with combination treatment of LEE011 and ruxolitinib. The results 
obtained shows that the targeting of both CDK4/6 and JAK1/2 are promising to 
develop better treatment alternatives for NKTCL.
INTRODUCTION
Natural killer/T-cell lymphoma (NKTCL) is an 
aggressive type of non-Hodgkin lymphoma characterised 
by a clonal proliferation of NK or T-cells, and patients 
often have poor survival rates [1, 2]. To date, treatments 
for NKTCL are still completely reliant on radiotherapy, 
chemotherapy or a combination of both, but these have 
been met with limited success with low complete response 
rates [1, 3, 4]. There is thus a compelling need to develop 
alternative strategies for NKTCL.
Recent studies have reported enriched and activated 
(phosphorylated) STAT3 protein in NKTCL [5–8]. The 
JAK-STAT pathway is essential for blood cells to respond 
to extracellular cytokines via cytokine receptors for 
proliferation and growth [9]. Signals from these receptors 
are often propagated through JAKs that can ultimately lead 
to the increase in cancer cells’ survival and proliferative 
indices via a change in transcription profile through STATs 
[10, 11]. The activated STAT3 status was subsequently 
found to be due to STAT3 activating mutations and/or the 
loss of receptor-type tyrosine-protein phosphatase κ [7, 12, 
13] and could be brought down to normal phosphorylated 
STAT3 levels upon JAK2 inhibition [7, 13]. These findings 
thus suggest that the STAT3 pathway could be a promising 
target for alternative NKTCL treatment.
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Additionally, our previous studies show that the 
epigenetic writer EZH2 is overexpressed in NKTCL [6, 
14]. EZH2 functions in the Polycomb repressive complex 
2 (PRC2) along with EED, SUZ12 and RbAp46/48 to 
trimethylate histone H3 lysine 27 (H3K27me3), a mark 
often associated with gene repression [15–17]. Contrary 
to its epigenetic repression function, we have found that 
EZH2 directly transcriptionally activates the CCND1 gene 
independent of its methyltransferase activity in NKTCL 
[14]. The CCND1 gene codes for cyclin D1, which when 
complexed with CDK4/6, promotes cell cycle progression 
from G1 to S phase. The overexpression of EZH2 thus 
likely conferred growth advantage to NKTCL cells by a 
corresponding upregulation of cyclin D1. Indeed, high 
levels of CCND1 transcript has been reported in NKTCL 
cell lines and upregulated cyclin D1 protein levels has 
been linked to poor prognosis and decreased survival in 
NKTCL patients [5, 18]. Hence, targeting CDK4/6 that is 
downstream of EZH2 could be promising for the treatment 
of NKTCL by inhibiting cell cycle progression.
Besides being essential to the pathogenesis of 
NKTCL, the JAK-STAT and EZH2-CDK4/6 pathways 
were noted to be upstream and downstream in the 
signalling pathway for cell growth respectively. As such, 
inhibiting them simultaneously should bring about a 
more robust and enhanced growth inhibition effect. Here, 
ruxolitinib and LEE011 (ribociclib) which targets JAK1/2 
and CDK4/6 [19, 20] respectively were tested against 
several NKTCL cell lines. Since these two drugs have 
successfully reached clinical trials, it is hoped that they 
will show promising results in NKTCL as well. By cell 
viability assay, it was clearly shown that though these two 
drugs are able to work individually to inhibit growth of 
NKTCL cells, a far greater growth inhibition could be 
achieved when they are used in combination. Changes 
in apoptotic and proliferative markers and cell cycle 
analysis further support this observation. These findings 
thus strongly provide a basis for a promising alternative 
treatment for NKTCL patients.
RESULTS
Growth inhibition on NKTCL cell lines was 
achieved with independent CDK4/6 and JAK1/2 
inhibition
To evaluate growth inhibitory efficacy of CDK4/6 
and JAK1/2 inhibition separately, the NKTCL cell 
lines were treated to a range of LEE011 and ruxolitinib 
concentrations. Cells were treated over a period of four 
days, with re-treatment on the second day to account for 
loss of drug stability over extended time in the incubator. 
Cell viability was assessed on Day 2, 3 and 4 of treatment. 
Growth inhibition was achieved with the two drugs 
independently across almost all the NKTCL cell lines 
tested as seen in the drop in cell viability as a function 
Figure 1: LEE011 and ruxolitinib inhibits growth in NKTCL cell lines. (A) Cell viability assay showed growth inhibition 
followed after independent LEE011 and ruxolitinib treatment. NKTCL cell lines were separately treated with LEE011 and ruxolitinib and 
cell viabilities were assessed at Day 2, 3 and 4. In each experiment, triplicate values were averaged and treated wells were normalised 
against control wells. Data is expressed as mean ± SEM from three independent experiments. The IC50 curves were plotted based on 
the variable-slope (four-parameter logistic model), fitted using the least squares model. (B) Clonogenic assay of single LEE011- and 
ruxolitinib-induced growth inhibition. Cell lines were treated with LEE011 or ruxolitinib at concentrations roughly corresponding to the 
respective IC50 values determined and checked for colony formation after two weeks (n = 3, * p<0.05, ** p<0.01, *** p<0.001, one-way 
ANOVA test).
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of drug concentration (Figure 1A). From the IC50 curves 
obtained, the IC50 values of LEE011 and ruxolitinib 
were then determined for each of the NKTCL cell lines 
(Table 1).
While the IC50 values of LEE011 fell within the 300 
nM to 3.2 uM that has been determined to be sensitive in 
neuroblastoma and T-ALL cell lines respectively [21, 22], 
the concentrations were nonetheless in the micromolar 
range. To confirm if the decrease in cell viability resulted 
from LEE011 is due to inhibition of its intended targets, 
we thus performed knockdown (KD) with CDK4/6 
siRNA which was compared to negative control siRNA. 
Decrease in cell viability followed after CDK4/6 KD 
(Supplementary Figure 1A). We also noted the extent of 
the drop in cell viability seemed to correlate with CDK4/6 
KD efficiency (Supplementary Figure 1B) as the less 
efficient CDK6 KD in KHYG is reflected in the least 
drop in cell viability. This thus suggests that the effect of 
LEE011 is likely due to CDK4/6 inhibition.
Growth inhibitory efficacies of the two agents were 
also then demonstrated in clonogenic assays which served 
to detect cells that have survived and retained progeny-
producing capacity following treatment [23]. Each cell 
line was treated with LEE011 and ruxolitinib separately 
at roughly the IC50 values obtained (Table 1) and was left 
to grow in the incubator for two weeks. In accordance to 
the cell viability assays, lesser number of colonies were 
observed in treated wells as compared to control wells 
across most NKTCL cell lines tested (Figure 1B). These 
results thus demonstrated that LEE011 and ruxolitinib are 
able to inhibit NKTCL cell growth individually.
LEE011 and ruxolitinib-induced growth 
inhibition is mediated through blocking cell cycle 
progression and STAT signalling respectively
Next, we studied how growth inhibition is achieved 
by LEE011 and ruxolitinib independently in NKTCL. For 
LEE011, it likely prevents progression into S phase by 
targeting CDK4/6 and inhibiting complex formation with 
cyclin D1 [19]. Indeed, upon LEE011 treatment, decreased 
cyclin E2 and phosphorylated retinoblastoma (Rb) levels 
were noted (Figure 2A). The mechanism of action by 
ruxolitinib, however, is not as clear due to JAK1/2 
involvement in other pathways besides STAT signalling. 
In particular, JAK2 phosphorylation of EZH2 at tyrosine 
641 is able to promote EZH2 degradation via the SCFβ-TrCP 
E3 ubiquitin ligase pathway in B cell lymphoma [24]. In 
addition, JAK3 phosphorylation of EZH2 was found to 
mediate EZH2 switch to non-canonical function [25]. It 
would thus be interesting to see if similar JAK2-mediated 
EZH2 degradation exists in NKTCL or that EZH2 switch 
to non-canonical function can be mediated by JAK1/2 as 
well. Gaining insights into the ruxolitinib effects on EZH2 
activity is essential given EZH2’s key role in NKTCL 
oncogenesis [14].
It was first confirmed if EZH2 was able to 
transcriptionally activate CCND1 gene expression. For 
this, control plasmids or plasmids containing EZH2 
wild-type (WT) sequence were transfected into NKYS, 
followed by measuring changes in CCND1 mRNA 
levels (Figure 2B). As seen, overexpression of EZH2 
WT led to a corresponding increase in CCND1 mRNA 
levels, affirming EZH2’s non-canonical function as 
transcriptional activator. This result provided proof that 
the non-canonical function of EZH2 can be monitored 
by cyclin D1 protein levels. Next, the three NKTCL 
cell lines were subjected to single ruxolitinib treatment 
at a concentration close to the IC50 values and changes 
in protein levels were studied. If a JAK2-mediated 
EZH2 degradation exists, an increase in the levels of 
EZH2, cyclin D1 and the H3K27me3 mark that EZH2 
catalyses would be expected upon JAK2 inhibition 
by ruxolitinib. Likewise, if JAK1/2 phosphorylation 
is able to cause a functional switch in EZH2 activity, 
an increase in H3K27me3 levels should follow after 
ruxolitinib treatment as EZH2 would be redirected back 
to catalyse the deposition of the H3K27me3 mark. None 
of these trends were seen in all the NKTCL cell lines 
tested (Figure 2C), indicating that JAK1/2 regulation on 
EZH2’s activity is absent in NKTCL. It is affirmative 
that a successful JAK1/2 inhibition by ruxolitinib 
was achieved as seen by the decrease in p-STAT3/5 
protein levels between control and treated cells. To 
note, KHYG was revealed to have a far lower STAT3/5 
basal phosphorylation level than the other two cell lines 
(Supplementary Figure 2), which might account for 
the lower ruxolitinib IC50 concentration. Nonetheless, 
LEE011 and ruxolitinib worked as intended to cause 
growth inhibition in NKTCL.
Table 1: IC50 values of LEE011 and ruxolitinib in all NKTCL cell lines tested
Day
NKYS NK-S1 KHYG
LEE011/μM Ruxolitinib/μM LEE011/μM Ruxolitinib/μM LEE011/μM Ruxolitinib/μM
2 15.0 0.920 23.7 0.581 5.21 0.298
3 6.00 0.219 20.8 0.327 3.11 0.126
4 7.32 0.241 19.4 0.269 2.19 0.0501
These values were obtained from the plots in Figure 1.
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Combination treatment of LEE011 and 
ruxolitinib induced synergistic growth inhibitory 
effects
Using the IC50 values of the two drugs determined 
for each NKTCL cell line, a range of concentrations 
around the IC50 value was selected for combination 
treatment. In contrast to the treatment conditions for 
single treatments, cells were only treated for a maximum 
period of three days, as any enhanced inhibitory effects 
should be observed at an earlier time point if LEE011 and 
ruxolitinib work synergistically with each other. As before, 
cells were re-treated at Day 2 and cell viabilities were 
assessed at Day 2 and 3 (Figure 3A). As seen, at a certain 
concentration of LEE011, a further drop in cell viability 
was noted when the cells were treated with ruxolitinib 
as well, and vice versa. These results thus suggest that 
combining LEE011 and ruxolitinib is able to produce an 
enhanced growth inhibitory effect in NKTCL cell lines.
However, simply by just noting the further drop 
in cell viability in combined as compared to single 
treatment is not sufficient to conclude on the synergism 
with using LEE011 and ruxolitinib together. To this 
end, determination of combination indices (CIs) of 
the two drugs at all combination concentrations was 
performed. A CI value of more than, equal and smaller 
than 1 is indicative of antagonism, additive and synergism 
respectively [26]. As most of the CI values obtained are 
less than 1, it strongly suggests that there is synergism 
at most concentrations of the two drugs and the two time 
points at which cell viabilities were assessed (Figure 
3B, refer to Supplementary Table 1 for the numerical CI 
values).
After noting synergistic growth inhibitory effect 
of LEE011 and ruxolitinib via cell viability assay, it 
is then imperative to understand how enhanced growth 
inhibition is achieved. For this purpose, we studied 
changes in the expression levels of proliferative and 
apoptotic markers in the NKTCL cell lines following 
drug treatment for three days (Figure 3C). Changes 
in cells’ proliferative capacity were assessed by the 
levels of the proliferative marker Ki-67 and cell-death 
inhibitor survivin [27, 28], while cleaved PARP and 
caspase 9 were probed for any increase in apoptosis 
[29, 30]. In general, we noticed a decrease in Ki-67 
and survivin levels from control to treated cells as 
early as 10 h following treatment. Importantly, Ki-
67 and survivin fell more in combination treatments 
compared to that of single treatments from around 
10 h that persisted up until 72 h, suggesting that the 
synergistic effect of LEE011 and ruxolitinib occurs 
at an early time point. As for the apoptotic markers, 
slightly higher levels of cleaved caspase 9 for all treated 
cells in contrast to control arose at 24 h. From 48 h, 
higher levels of cleaved caspase 9 were detected in cells 
treated with both drugs than cells that received single 
drug. Cleaved PARP levels remained relatively constant 
throughout all time points in NKYS and NK-S1 cells, 
but increased further in combination treatment from 48 
h in KHYG cells. These results thus provide promising 
leads into the mechanism of growth inhibition of 
LEE011 and ruxolitinib combination treatment.
Figure 2: LEE011 and ruxolitinib inhibit growth by blocking cell cycle progression and STAT signalling respectively. 
(A) Western blot showing that LEE011 blocks CDK4/6 phosphorylation of Rb and the subsequent expression of cyclin E2. Cells were 
treated with their respective LEE011 IC50 concentrations and harvested 3 and 9 h after. (B) RT-qPCR results of mRNA harvested from 
NKYS cells that were either transfected with control and EZH2 WT plasmids after 24 h. Relative fold change of EZH2 and CCND1 mRNA 
levels were obtained by normalising to control cells. Differences were determined to be statistically significant (n = 3, * p<0.05, ** p< 0.01, 
one-tailed student’s t-test). (C) NKYS, NK-S1 and KHYG cells were treated with 200 nM ruxolitinib and harvested after 3, 6, 9 and 12 h 
later. Blots shown for each cell line are representative blots from the same experiment, among two other independent biological replicates.
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Beside studying levels of proliferative and 
apoptotic markers, knowing at which stage of the cell 
cycle is growth inhibited is also important for us to 
further understand the mechanism of action of LEE011 
and ruxolitinib in NKTCL. Thus, we carried out flow 
cytometric analysis of cell cycle populations on KHYG 
after treatment for 48 h (Figure 3D). As seen, there 
was an increase in sub-G1 population and decrease in 
both S and G2/M phase populations going from single 
to combination treatment. Particularly the decrease 
in S phase between single LEE011 and combination 
treatment was significant. In summary, this finding 
further corroborated the synergistic relationship between 
LEE011 and ruxolitinib, in that inhibiting JAK1/2 on top 
Figure 3: LEE011 and ruxolitinib displayed synergistic relationship on achieving growth inhibition in NKTCL cell 
lines. (A) Cell viability assay showed enhanced growth inhibition with dual LEE011 and ruxolitinib treatment. The cells were subjected 
to single or combined LEE011 treatment as indicated and cell viabilities were assessed on Day 2 and 3. In each experiment, values from 
triplicate wells were averaged and treatment wells were normalised against control wells. Data is expressed as mean ± SEM from three 
independent experiments. (B) Fa-CI plots for the cells on the days cell viabilities were assessed revealed a synergistic growth inhibition effect 
with dual treatment of LEE011 and ruxolitinib. In the Fa-CI plots, the dashed line where CI = 1 indicates an additive reaction between the 
two drugs. Points that fall above (CI>1) and below (CI<1) the dashed line denote antagonism and synergism respectively. (C) Western blot 
analysis of proliferative and apoptotic markers following LEE011 and ruxolitinib combined treatment. Cells were singly and combine treated 
to LEE011 and ruxolitinib at concentrations as indicated. Protein lysates from 10 and 24 h were ran on the same SDS-PAGE gel, while that of 
48 and 72 h were ran on a separate gel. In general, a decrease in proliferative markers and increase in apoptotic markers in combine treatment 
as compared to single treatment were noted across different time points. (D) Evaluation of combination treatment using flow cytometric 
analysis of cell cycle populations. KHYG cells were treated with LEE011 and ruxolitinib at concentrations as indicated. Significant decrease 
in S phase populations was noted between single LEE011 and combine treatment (n = 3, * p<0.05, one-way ANOVA test).
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of CDK4/6 could further prevent entry into S phase of 
the cell cycle.
DISCUSSION
The low success rates that current treatments on 
NKTCL are showing [1, 3, 4] has urged us to discover 
better treatment alternatives. Several key findings in 
recent years have helped to shed light on the pathogenesis 
of NKTCL. In particular, deregulation of JAK-STAT 
signalling as well as overexpression of cyclin D1 by 
upregulated EZH2 levels have been noted to confer 
oncogenic potential in NKTCL [7, 14]. These findings 
thus suggested for the dual targeting of JAKs and cyclin 
D1 in NKTCL.
Here, we tested a combination of ruxolitinib and 
LEE011 that inhibit JAK1/2 and CDK4/6 respectively 
against several NKTCL cell lines, namely NKYS, 
KHYG and NK-S1. We first confirmed the growth 
inhibitory efficacy of separate LEE011 and ruxolitinib 
treatment via cell viability assays and clonogenic assay. 
The higher IC50 concentrations noted for LEE011 as 
compared to ruxolitinib across all NKTCL cell lines 
tested might suggest a possibility that inhibition of 
JAK1/2 produces a more potent effect than CDK4/6 
inhibition. This might be explained by the coupling of 
JAKs to the activation of pathways that promote cell 
survival [10]. Therefore, while LEE011 and ruxolitinib 
both decrease cell proliferation, ruxolitinib can affect 
survivability as well.
The effect that LEE011 has on NK-S1 was 
observably less effective than in NKYS and KHYG, with 
just about 20% decrease in cell viability at concentrations 
as high as 10 μM, which is also reflected in a higher 
IC50 value. This difference in LEE011 growth inhibitory 
efficacy between the NKTCL cell lines could be due to 
the mutational status of JAK3 in them. While NKYS 
and KHYG possess wild-type JAK3, NK-S1 carries a 
homozygous JAK3A572V mutation, which makes JAK3 
constitutively active [31]. The constitutively active JAK3 
could allow for the persistence of pro-survival and pro-
proliferation signals in NK-S1 cells, attenuating the effect 
of LEE011.
Subsequently, it was concluded that a synergistic 
relationship exists between LEE011 and ruxolitinib as the 
CI values were less than 1 at most concentrations tested. 
Still the presence of CI values greater than 1 should 
not be ignored. In general, a CI value of more than 1 
was observed when low concentrations of LEE011 and 
ruxolitinib were used. However, this does not mean that 
the two drugs work antagonistically at low concentrations 
and synergistically at high concentrations. Rather, it is 
plausible that the growth inhibitory effects obtained at 
these low concentrations in combination were not very 
different from that of single treatment. Any increase in 
cell viability in combination from single treatment at 
low concentrations could be the result of experimental 
variations.
Similarly, the strikingly high CI values in KHYG 
cells (Supplementary Table 1, highlighted in grey) could 
be due to the same reasons as well. In particular, the 5 nM 
ruxolitinib dose might have been too low to be included 
for the assessment of combination effect. This is in view 
that the IC50 concentrations determined for ruxolitinib at 
Day 2 and 3 were close to 200 nM, which is 40-fold higher 
than 5 nM. This could thus account for the high CIs noted 
at 5 nM ruxolitinib at varying LEE011 concentrations. 
Considering that CI values were less than 1 in most 
other instances where sufficiently high concentrations 
of LEE011 and ruxolitinib were used, it is thus sound to 
conclude that there is a synergistic effect of inhibiting both 
CDK4/6 and JAK1/2 in NKTCL.
The synergistic relationship between LEE011 
and ruxolitinib was further confirmed by cell cycle 
analysis, with significant difference going from single 
to combination treatment noted at S phase. Synergism 
was also evidenced by changes in proliferation and 
apoptotic markers, which showed that combination 
treatment causes further decrease in proliferation and 
increase in apoptosis. Difference in Ki-67 levels arose 
as early as 10 h, suggesting that the synergistic effect 
of LEE011 and ruxolitinib in inhibition of proliferation 
occurs at an early time point. This was then followed by 
a loss of the anti-apoptotic molecule survivin at 24 h. 
The loss of survivin then possibly promoted apoptotic 
death as seen by an increase in cleaved caspase 9 levels 
from 48 h onwards. Cell death appears to have occurred 
via the intrinsic apoptotic pathway, given caspase 9’s 
exclusive involvement in only this apoptotic pathway 
[29]. Therefore, the examination of the proliferative 
and apoptotic markers also revealed the synergistic 
relationship between LEE011 and ruxolitinib in NKTCL.
The results of LEE011 and ruxolitinib combination 
treatment thus provided insights into a promising new 
treatment for NKTCL. The effect of JAK1/2 inhibition 
with ruxolitinib agrees with other studies where NKTCL 
growth inhibition was similarly achieved via JAK2 
inhibition using AG490 [7, 8]. However, ruxolitinib 
is favoured here as AG490 is less potent and has been 
reported to block many other Ser/Thr kinases, which 
would complicate results interpretation [32]. Our data 
on ruxolitinib in NKTCL are also in concordance with 
recent publications [33, 34]. In addition, the combination 
use of LEE011 and ruxolitinib have been demonstrated 
to be successful in the treatment of myelofibrosis and is 
currently undergoing phase I of clinical trials [35, 36]. It 
is thus hoped that the success of LEE011 and ruxolitinib 
combination use for myelofibrosis can be leveraged upon 
to push forward an alternative treatment for NKTCL.
Single ruxolitinib treatment caused no change 
in EZH2, cyclin D1 and H3K27me3 levels, indicating 
absence of JAK1/2 regulation on EZH2’s level and 
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activity. However, it is possible that JAK3 is the 
predominent regulator of EZH2 activity in NKTCL and 
hence no changes were observed following JAK1/2 
inhibition. This is consistent with our previous observation 
that inhibition of JAK3 with JAK3 inhibitor PF956980 can 
target deregulated EZH2 pathway using [25].
MATERIALS AND METHODS
Cell culture
The cell lines used in this study included NKYS, 
NK-S1 [37, 38] (both NK lymphoma cell lines and KHYG 
[39] (NK leukaemia cell line). NKYS and KHYG cells 
were cultured in Roswell Park Memorial Institution media 
(RPMI; Hyclone, USA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Hyclone), 1% each 
of penicillin-streptomycin (P/S) and L-glutamine (both 
from Biowest, France). NKYS and KHYG were also 
supplemented with 20 ng/ml and 40 ng/ml recombinant 
human interleukin-2 (IL-2; Miltenyi Biotec, Germany) 
respectively. NK-S1 was cultured in Dulbecco’s Modified 
Eagles Medium (DMEM; Hyclone) without sodium 
pyruvate, supplemented with 10% FBS (Hyclone), 10% 
inactivated horse serum (Life Technologies, USA) and 1% 
each of P/S and L-glutamine (Biowest). All cell lines were 
grown in humidified incubators at 37°C with 5% CO2.
Drugs
Drugs used in this study included the CDK4/6 
inhibitor, LEE011 (Novartis, Switzerland), and the JAK1/2 
inhibitor, ruxolitinib (Invivogen, USA).
Cell viability assay
Cells were seeded at 2 × 104 cells/100μl/well in 
96-well plates in triplicates and treated with or without 
the respective drugs at various concentrations for a 
maximum period of four days. The cells were re-treated 
at Day 2 to account for loss of drug stability in the 
incubator over extended time period. Cell viability was 
assessed at Day 2, 3 and 4 using the CellTiter-Glo 2.0 
assay (Promega, USA) as per manufacturer’s protocol 
and luminescence was read using the Infinite M200 plate 
reader (Tecan, Switzerland).
Protein concentration estimation
Cells were lysed in radioimmunoprecipitation assay 
buffer and were subjected to sonication. Protein lysates 
were 10-fold diluted and standards were prepared by serial 
dilution of 1 mg/ml bovine serum albumin (BSA; Hyclone). 
Standards and samples were all done in triplicates. 200 μl of 
Quick Start™ Bradford reagent (Bio-Rad, USA) was then 
added and the intensity of the resulting blue colour was 
measured at a wavelength of 595 nm.
Western blotting
Appropriate percentage of sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to resolve equal amounts of protein samples. The resolved 
protein samples were then transferred to polyvinylidene 
difluoride membrane (Bio-Rad). After which, the membrane 
was blocked in 5% BSA solution and incubated overnight 
with primary antibodies at 4°C, followed by incubation 
for 1 hour with secondary antibodies at room temperature. 
Primary antibodies used included BioLegend antibody Ki-
67 (652402), Cell Signalling antibody cyclin D1 (2978), 
cleaved caspase 9 (9501), cleaved poly(ADP-ribose) 
polymerase (PARP; 9541), EZH2 (3147), H3 (9715), 
H3K27me3 (9733, 9756), p-STAT3 (9131, sc-8059), 
p-STAT5 (9351, 9356), survivin (2802), and SantaCruz 
antibody actin (sc-1615HRP), CDK4 (sc-23896), CDK6 
(sc-7961), GAPDH (sc-47724 HRP), STAT3 (sc-482), 
STAT5 (sc-835). Secondary antibodies used included 
SantaCruz antibody goat anti-rabbit IgG-HRP (sc-2030) 
and goat anti-mouse IgG-HRP (sc-2031). Blotted proteins 
were detected and visualised using Amersham™ ECL™ 
start Western Blotting detection reagent (GE Healthcare, 
UK), Luminata™ Crescendo Western HRP substrate 
(Millipore, USA) or SuperSignal™ West Femto Maximum 
Sensitivity Substrate (Thermo Scientific, USA). Where 
necessary, p-STAT3 and p-STAT5 antibodies were stripped 
using Restore™ Western Blot Stripping Buffer (Thermo 
Scientific) following manufacturer’s recommendations to 
re-probe for STAT3 and STAT5 respectively.
Clonogenic assay
5000 NKYS, KHYG and NK-S1 cells were seeded 
separately into each well of a 6-well plate in StemMACS 
hematopoietic stem cell-colony forming units (HSC-
CFU) basic methylcellulose medium (Miltenyi Biotec). 
Appropriate concentration of IL-2, LEE011 and ruxolitinib 
were also added into each well. The plates were placed 
in humidified incubators at 37°C with 5% CO2 for two 
weeks, after which colony formation was scored with an 
inverted microscope.
Plasmid and siRNA transfection
Transfection on NKTCL cell lines were done 
using Neon® transfection system (Invitrogen) following 
manufacturer’s protocol at the electroporation parameters 
of 1250V, 10 ms width and three pulses. For each 
transfection, 1 × 106 cells were used. For overexpression 
experiment, NKYS cells were transfected with 2 μg 
control (pCMV-HA-GFP) or EZH2 (pCMV-HA-
EZH2WT; kindly gifted by Dr Yu Qiang of GIS) vector 
plasmid, 0.5 μg green fluorescence protein plasmid 
(pMAX-GFP) and 0.5 μg puromycin-resistant plasmid. 
For knockdown experiment, 200 nM human non-targeting 
siRNA negative control #1 (4390844) or 100 nM each of 
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siRNA against CDK4 (s2822) and CDK6 (s51) were used 
and were all purchased from Life Technology Ambion.
Quantitative RT-PCR
Cells were lysed using QIAzol lysis reagent 
(Qiagen, Germany) and total RNA was isolated using the 
RNeasy Mini Kit (Qiagen). The extracted RNA was then 
converted to cDNA with the iScript Reverse Transcription 
Supermix (Bio-Rad). The mRNA levels of EZH2, CCND1 
and housekeeping gene GAPDH were then quantitated 
using iTaq™ Universal SYBR® Green Supermix (Bio-
Rad) according to manufacturer’s recommendations, using 
their respective primers (Supplementary Table 2).
Flow cytometric assay for cell cycle
To measure the effect of LEE011 and ruxolitinib 
combinatorial treatment on apoptosis, NKYS, KHYG and 
NK-S1 were separately treated at 2 × 105 cells/ml in 10 cm 
dishes at appropriate drug concentrations, and harvested 
48 h later. Cells were washed and fixed in ice-cold 70% 
ethanol for 2 h before further incubation at -20°C for up 
to 24 h. Immediately before flow cytometric analysis, 
the cells were treated with RNase A (Qiagen) and stained 
with propidium iodide (Invitrogen, USA) for 30 min. 
Collection and analysis of data was done using BD LSR II 
Special Order System (BD Biosciences, USA).
Statistical analysis
All graphs are expressed as mean ± SEM, from 
three independent experiments. Difference between 
samples were evaluated by unpaired one-tailed student’s 
t-test or one-way ANOVA test where appropriate, 
and p-values < 0.05 were considered as statistically 
significant. IC50 curves (variable slope) were plotted 
using GraphPad Prism 6.1 (GraphPad Software, USA) 
and IC50 values over different treatment time points were 
compared via the extra sum-of-squares F test. Synergistic 
effects from drug combination was determined via the 
quantitative method using CompuSyn [26] (version 1.0, 
ComboSyn, Inc.).
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